{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:15:52Z","timestamp":1790810152820,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,19]]},"DOI":"10.7759\/cureus.9871","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T16:31:24Z","timestamp":1597854684000},"source":"Crossref","is-referenced-by-count":13,"title":["How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome"],"prefix":"10.7759","author":[{"given":"Ilmaben S","family":"Vahora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Tsouklidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0084-x","article-title":"American College of Gastroenterology monograph on management of irritable bowel syndrome","volume":"113","author":"Ford AC","year":"2018","unstructured":"Ford AC, Moayyedi PD, Chey W, Harris LA, Lacy BE, Saito YA, Quigley EM. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018, 113:1-18. 10.1038\/s41395-018-0084-x","journal-title":"Am J Gastroenterol"},{"key":"ref2","article-title":"Management of Irritable Bowel Syndrome in Primary Care","author":"Stamboldjiev T","year":"2011","unstructured":"Stamboldjiev T. Management of Irritable Bowel Syndrome in Primary Care. St. Catherine University, St. Paul; 2011."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0884533608318677","article-title":"Behavioral and complementary approaches for the treatment of irritable bowel syndrome","volume":"23","author":"Wald A","year":"1999","unstructured":"Wald A, Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Pract. 1999, 23:284-92. 10.1177\/0884533608318677","journal-title":"Nutr Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/486067","article-title":"Psychopharmacological treatment and psychological interventions in irritable bowel syndrome","volume":"2012","author":"Sinagra E","year":"2012","unstructured":"Sinagra E, Romano C, Cottone M. Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterol Res Pract. 2012, 2012:486067. 10.1155\/2012\/486067","journal-title":"Gastroenterol Res Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth GF","year":"2006","unstructured":"Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006, 130:1480-1491. 10.1053\/j.gastro.2005.11.061","journal-title":"Gastroenterology"},{"key":"ref6","unstructured":"Antidepressant medications improve irritable bowel syndrome symptoms. (2020). Accessed. 04\/27\/2020: https:\/\/medicaldialogues.in\/pediatrics-neonatology\/news\/antidepressant-medications-improve-irritable-bowel-syndrome-s...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i36.6593","article-title":"New therapeutic perspectives in irritable bowel syndrome: targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond","volume":"23","author":"Sinagra E","year":"2017","unstructured":"Sinagra E, Morreale G, Mohammadian G, et al.. New therapeutic perspectives in irritable bowel syndrome: targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol. 2017, 23:6593-6627. 10.3748\/wjg.v23.i36.6593","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwy071","article-title":"AGA technical review on irritable bowel syndrome","volume":"123","author":"Drossman DA","year":"2002","unstructured":"Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002, 123:2108-2131. 10.1093\/jcag\/gwy071","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09712-X","article-title":"Irritable bowel syndrome: a little understood organic bowel disease?","volume":"360","author":"Talley NJ","year":"2002","unstructured":"Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease?. Lancet. 2002, 360:555-564. 10.1016\/S0140-6736(02)09712-X","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.032","article-title":"Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients","volume":"139","author":"Faure C","year":"2010","unstructured":"Faure C, Patey N, Gauthier C, Brooks EM, Mawe GM. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010, 139:249-258. 10.1053\/j.gastro.2010.03.032","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwy071","article-title":"Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)","volume":"2","author":"Moayyedi P","year":"2019","unstructured":"Moayyedi P, Andrews C, MacQueen G, et al.. Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). J Can Assoc Gastroenterol. 2019, 2:6-29. 10.1093\/jcag\/gwy071","journal-title":"J Can Assoc Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.14","article-title":"Irritable bowel syndrome","volume":"2","author":"Enck P","year":"2016","unstructured":"Enck P, Aziz Q, Barbara G, et al.. Irritable bowel syndrome. Nat Rev Primers. 2016, 2:16014. 10.1038\/nrdp.2016.14","journal-title":"Nat Rev Primers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_103","article-title":"Serotonergic mechanisms regulating the GI tract: experimental evidence and therapeutic relevance","volume":"239","author":"Terry N","year":"2017","unstructured":"Terry N, Margolis K. Serotonergic mechanisms regulating the GI tract: experimental evidence and therapeutic relevance. Gastrointest Pharm. 2017, 239:319-342. 10.1007\/164_2016_103","journal-title":"Gastrointest Pharm"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.169802","article-title":"Irritable bowel syndrome: is it \u201cirritable brain\u201d or \u201cirritable bowel\u201d?","volume":"6","author":"Padhy S","year":"2015","unstructured":"Padhy S, Sahoo S, Mahajan S, Sinha S. Irritable bowel syndrome: is it \u201cirritable brain\u201d or \u201cirritable bowel\u201d?. J Neurosci Rural Pract. 2015, 6:568-577. 10.4103\/0976-3147.169802","journal-title":"J Neurosci Rural Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666150825220524","article-title":"An endogenous tachykinergic NK2\/NK3 receptor cascade system controlling the release of serotonin from colonic mucosa","volume":"13","author":"Kojima S","year":"2015","unstructured":"Kojima S, Tohei A, Ikeda M, Anzai N. An endogenous tachykinergic NK2\/NK3 receptor cascade system controlling the release of serotonin from colonic mucosa. Curr Neuropharmacol. 2015, 13:830-835. 10.2174\/1570159X13666150825220524","journal-title":"Curr Neuropharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12617","article-title":"Serotonin and colonic motility","volume":"27","author":"Kending D","year":"2015","unstructured":"Kending D, Grider J. Serotonin and colonic motility. Neurogastroenterol Motil. 2015, 27:899-905. 10.1111\/nmo.12617","journal-title":"Neurogastroenterol Motil"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2013.256230","article-title":"Important role of mucosal serotonin in colonic propulsion and peristaltic reflexes: in vitro analyses in mice lacing tryptophan hydroxylase","volume":"591","author":"Heredia D","year":"2013","unstructured":"Heredia D, Gershon M, Koh S, Corrigan R, Okamoto T, Smith T. Important role of mucosal serotonin in colonic propulsion and peristaltic reflexes: in vitro analyses in mice lacing tryptophan hydroxylase. J Physiol. 2013, 591:5939-5957. 10.1113\/jphysiol.2013.256230","journal-title":"J Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i36.8137","article-title":"Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome","volume":"22","author":"Cao D","year":"2016","unstructured":"Cao D, Xu M, Wang S, et al.. Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. World J Gastroenterol. 2016, 22:8137-8148. 10.3748\/wjg.v22.i36.8137","journal-title":"World J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i3.338","article-title":"Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome","volume":"24","author":"Cao Y","year":"2018","unstructured":"Cao Y, Feng L , Liu Y, et al.. Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. World J Gastroenterol. 2018, 24:338-350. 10.3748\/wjg.v24.i3.338","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181b37e8c.","article-title":"Serotonin transporter promoter variant: analysis in Indian IBS patients and control population","volume":"43","author":"Sikander A","year":"2009","unstructured":"Sikander A, Rana SV, Sinha SK, et al.. Serotonin transporter promoter variant: analysis in Indian IBS patients and control population. J Clin Gastroenterol. 2009, 43:957-961. 10.1097\/MCG.0b013e3181b37e8c.","journal-title":"J Clin Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)04197-7","article-title":"Serotonin transporter gene polymorphism in irritable bowel syndrome","volume":"97","author":"Pata C","year":"2002","unstructured":"Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol. 2002, 97:1780-1784. 10.1016\/S0002-9270(02)04197-7","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519859144","article-title":"Association between polymorphisms in the serotonin transporter gene-linked polymorphic region and risk for irritable bowel syndrome in China: evidence based on a meta-analysis","volume":"47","author":"Jia Z","year":"2019","unstructured":"Jia Z, Wang L, Yu B, Li Q, Xi D. Association between polymorphisms in the serotonin transporter gene-linked polymorphic region and risk for irritable bowel syndrome in China: evidence based on a meta-analysis. J Int Med Res. 2019, 47:2810-2818. 10.1177\/0300060519859144","journal-title":"J Int Med Res"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120447","article-title":"Mechanisms of intestinal serotonin transporter (SERT) upregulation by TGF-\u03b21 induced non-Smad pathways","volume":"10","author":"Nazir S","year":"2015","unstructured":"Nazir S, Kumar A, Chatterjee I, et al.. Mechanisms of intestinal serotonin transporter (SERT) upregulation by TGF-\u03b21 induced non-Smad pathways. PLoS One. 2015, 10:e0120447.","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.10976","article-title":"Glucagon-like peptide-1 analog exendin\u20114 modulates serotonin transporter expression in intestinal epithelial cells","volume":"21","author":"Cui X","year":"2020","unstructured":"Cui X, Zhao X, Wang Y, Yang Y, Zhang H. Glucagon-like peptide-1 analog exendin\u20114 modulates serotonin transporter expression in intestinal epithelial cells. Mol Med Rep. 2020, 21:1934-1940. 10.3892\/mmr.2020.10976","journal-title":"Mol Med Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i36.6593","article-title":"Therapeutic perspective in irritable bowel syndrome; targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond","volume":"23","author":"Sinagra E","year":"2017","unstructured":"Sinagra E, Morreale G, Mohammadian G, et al.. Therapeutic perspective in irritable bowel syndrome; targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol. 2017, 23:6593-6627. 10.3748\/wjg.v23.i36.6593","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.04.032","article-title":"Management options for irritable bowel syndrome","volume":"93","author":"Camilleri M","year":"2018","unstructured":"Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018, 93:1858-1872. 10.1016\/j.mayocp.2018.04.032","journal-title":"Mayo Clin Proc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172846","article-title":"Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zheng Y","year":"2017","unstructured":"Zheng Y, Yu T, Tang Y, et al.. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017, 12:0172846-10. 10.1371\/journal.pone.0172846","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.10.047","article-title":"Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women","volume":"150","author":"Fukudo S","year":"2016","unstructured":"Fukudo S, Kinoshita Y, Okumura T, et al.. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016, 150:358-366.","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0734-2","article-title":"Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Qi Q","year":"2018","unstructured":"Qi Q, Zhang Y, Chen F, Zuo X, Li Y. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018, 18:5. 10.1186\/s12876-017-0734-2","journal-title":"BMC Gastroenterol"},{"key":"ref30","article-title":"Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom","volume":"35","author":"Olden K","year":"2019","unstructured":"Olden K, Chey W, Shringapure R, et al.. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom. Gastroenterology. 2019, 35:461-472.","journal-title":"Gastroenterology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818771674","article-title":"Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint","volume":"11","author":"Lacy B","year":"2018","unstructured":"Lacy B, Nicandro J, Chuang E, Earnest D. Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Ther Adv Gastroenterol. 2018, 11:1756284818771674. 10.1177\/1756284818771674","journal-title":"Ther Adv Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15420","article-title":"Abnormalities of mucosal serotonin metabolism and 5\u2010HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhea predict responsiveness to ondansetron","volume":"50","author":"Gunn D","year":"2019","unstructured":"Gunn D, Garsed K, Lam C, et al.. Abnormalities of mucosal serotonin metabolism and 5\u2010HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhea predict responsiveness to ondansetron. Aliment Pharmacol Ther. 2019, 50:538-546. 10.1111\/apt.15420","journal-title":"Aliment Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/17562848198789","article-title":"Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions","volume":"12","author":"Cangemi DJ","year":"2019","unstructured":"Cangemi DJ, Lacy BE. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Therap Adv Gastroenterol. 2019, 12:1756284819878950. 10.1177\/17562848198789","journal-title":"Therap Adv Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1159\/000201377","article-title":"Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)","volume":"57","author":"Goldberg PA","year":"1996","unstructured":"Goldberg PA, Kamm MA, Setti-Carraro P, Van Der Siip JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion. 1996, 57:478-83. 10.1159\/000201377","journal-title":"Digestion"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3562-6","article-title":"Treatment of irritable bowel syndrome with diarrhea using titrated ondansetron (TRITON): study protocol for a randomized controlled trial","volume":"20","author":"Gunn D","year":"2019","unstructured":"Gunn D, Fried R, Lalani R, et al.. Treatment of irritable bowel syndrome with diarrhea using titrated ondansetron (TRITON): study protocol for a randomized controlled trial. Trials. 2019, 20:517. 10.1186\/s13063-019-3562-6","journal-title":"Trials"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S93698","article-title":"Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome","volume":"9","author":"Lacy B","year":"2016","unstructured":"Lacy B. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016, 9:7-17. 10.2147\/IJGM.S93698","journal-title":"Int J Gen Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127815","article-title":"Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis","volume":"10","author":"Xie C","year":"2015","unstructured":"Xie C, Tang Y, Wang Y, et al.. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One. 2015, 10:0127815. 10.1371\/journal.pone.0127815","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.42747","article-title":"Pharmacological approach for managing pain in irritable bowel syndrome: a review article","volume":"7","author":"Chen L","year":"2017","unstructured":"Chen L, Ilham S, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth Pain Med. 2017, 7:42747. 10.5812\/aapm.42747","journal-title":"Anesth Pain Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/34925-how-serotonin-level-fluctuation-affects-the-effectiveness-of-treatment-in-irritable-bowel-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:59Z","timestamp":1707506699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/34925-how-serotonin-level-fluctuation-affects-the-effectiveness-of-treatment-in-irritable-bowel-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.9871","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,19]]}}}